Biogen (NASDAQ:BIIB) reported upbeat earnings for the first quarter on Wednesday.

The company posted quarterly earnings of $3.57 per share which beat the analyst consensus estimate of $3.01 per share. The company reported quarterly sales of $2.478 billion which beat the analyst consensus estimate of $2.255 billion.

Biogen cut its FY2026 adjusted EPS guidance from $15.25-$16.25 to $14.25-$15.25.

Biogen shares fell 1.3% to trade at $191.84 on Thursday.

These analysts made changes to their price targets on Biogen following earnings announcement.

  • Wedbush analyst Laura Chico maintained Biogen with a Neutral and raised the price target from $191 to $196.
  • Guggenheim analyst Yatin Suneja maintained the stock with a Buy and raised the price target from $246 to $260.

Considering buying BIIB stock? Here’s what analysts think:

Photo via Shutterstock